Clinical improvement after Essure® devices removal: a systematic review.


Journal

The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception
ISSN: 1473-0782
Titre abrégé: Eur J Contracept Reprod Health Care
Pays: England
ID NLM: 9712127

Informations de publication

Date de publication:
Aug 2023
Historique:
medline: 25 7 2023
pubmed: 19 7 2023
entrez: 19 7 2023
Statut: ppublish

Résumé

Essure® implant is a permanently implanted minimally invasive birth control device for women (female sterilisation) widely used between 2002 and 2018. Many adverse events were reported by patients. Increasingly removal procedures have been performed in symptomatic patients. However, there is a lack of in-depth studies on clinical improvement after Essure® removal. We aimed to review all clinical studies about symptoms and quality of life (QoL) after removal procedures. A review of literature in electronic search in Medline and Embase databases from January 2002 to January 2022 using the following keywords: Essure; Essure removal; quality of life; symptomatology improvement. Out of 764 articles in the initial database, 18 clinical studies were eligible for inclusion in our literature review. Overall clinical improvement rates after removal ranged from 21% to 98%. All symptoms were less frequent after Essure® removal, although with large discrepancies between studies. Lack of improvement was reported between 1% to 15% of patients. Rate of patients with improvement of QoL after removal ranged from 58 to 98%. The pain was reported as significantly reduced after the surgery. In the available literature, Essure® removal in symptomatic patients may improve symptoms and quality of life. This should be discussed in the benefits and risks ratio before deciding on the best option of management. Essure® removal in symptomatic patients may improve symptoms and quality of life.

Autres résumés

Type: plain-language-summary (eng)
Essure® removal in symptomatic patients may improve symptoms and quality of life.

Identifiants

pubmed: 37466355
doi: 10.1080/13625187.2023.2236741
doi:

Types de publication

Systematic Review Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

238-248

Auteurs

Chloe Miguet-Bensouda (C)

Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, Lyon, France.

Francois Parant (F)

Trace Element Analysis Laboratory, Biochemistry Department, CBAPS, Centre hospitalier Lyon-Sud, Chemin du Grand-Revoyet, University hospital of Lyon, Pierre-Benite, France.

Guillaume Grenet (G)

Department of Pharmacotoxicology, University Hospital of Lyon, Lyon, France.

Emanuele Cerruto (E)

Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, Lyon, France.

Erdogan Nohuz (E)

Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, Lyon, France.

Gautier Chene (G)

Department of Gynecology, Hôpital Femme Mère Enfant, HFME, University Hospital of Lyon, Lyon, France.
Claude Bernard university of Lyon 1, Lyon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH